BioVie Inc. (BIVI) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
20/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinBIVI / S&P 38.57% / 15.20% |
LoseBIVI / S&P BIVI unavailable / 15.00% |
LoseBIVI / S&P -78.28% / 50.40% |
| 2026-Q11/3 |
WinBIVI / S&P 20.69% / -4.33% |
LoseBIVI / S&P BIVI unavailable / 11.30% |
LoseBIVI / S&P -95.08% / 27.70% |
| 2025-Q40/3 |
LoseBIVI / S&P -38.95% / 2.65% |
LoseBIVI / S&P BIVI unavailable / 9.00% |
LoseBIVI / S&P -94.09% / 13.40% |
| 2025-Q30/3 |
LoseBIVI / S&P -79.46% / 8.12% |
LoseBIVI / S&P BIVI unavailable / 4.61% |
LoseBIVI / S&P -89.02% / 13.45% |
| 2025-Q20/3 |
LoseBIVI / S&P -5.61% / 10.94% |
LoseBIVI / S&P BIVI unavailable / 4.83% |
LoseBIVI / S&P -80.17% / 10.63% |
| 2025-Q11/3 |
LoseBIVI / S&P -51.00% / -4.27% |
LoseBIVI / S&P BIVI unavailable / 4.98% |
WinBIVI / S&P 271.74% / 10.57% |
| 2024-Q42/3 |
WinBIVI / S&P 66.67% / 2.41% |
LoseBIVI / S&P BIVI unavailable / 5.25% |
WinBIVI / S&P 303.86% / 6.15% |
| 2024-Q31/3 |
LoseBIVI / S&P -70.07% / 5.89% |
LoseBIVI / S&P BIVI unavailable / 5.89% |
WinBIVI / S&P 328.94% / 6.11% |
| 2024-Q21/3 |
LoseBIVI / S&P -24.20% / 4.28% |
LoseBIVI / S&P BIVI unavailable / 5.38% |
WinBIVI / S&P 373.03% / 5.12% |
| 2024-Q11/3 |
LoseBIVI / S&P -58.02% / 10.56% |
LoseBIVI / S&P BIVI unavailable / 5.71% |
WinBIVI / S&P 1196.95% / 5.59% |
| 2023-Q41/3 |
LoseBIVI / S&P -63.05% / 11.69% |
LoseBIVI / S&P BIVI unavailable / 6.81% |
WinBIVI / S&P 1222.15% / 7.78% |
| 2023-Q31/3 |
LoseBIVI / S&P -20.88% / -3.27% |
LoseBIVI / S&P BIVI unavailable / 7.52% |
WinBIVI / S&P 1387.60% / -5.03% |
| 2023-Q21/3 |
LoseBIVI / S&P -46.66% / 8.74% |
LoseBIVI / S&P BIVI unavailable / 9.50% |
WinBIVI / S&P 1358.49% / -8.57% |
| 2023-Q10/3 |
LoseBIVI / S&P 3.99% / 7.50% |
LoseBIVI / S&P BIVI unavailable / 10.77% |
LoseBIVI / S&P -84.97% / -15.69% |
| 2022-Q41/3 |
WinBIVI / S&P 212.05% / 7.56% |
LoseBIVI / S&P BIVI unavailable / 11.88% |
LoseBIVI / S&P -86.27% / -17.99% |
| 2022-Q31/3 |
WinBIVI / S&P 71.72% / -4.88% |
LoseBIVI / S&P BIVI unavailable / 13.47% |
LoseBIVI / S&P -88.85% / -1.41% |
| 2022-Q20/3 |
LoseBIVI / S&P -69.28% / -16.10% |
LoseBIVI / S&P BIVI unavailable / 13.71% |
LoseBIVI / S&P -94.23% / 11.04% |
| 2022-Q11/3 |
WinBIVI / S&P 4.89% / -4.60% |
LoseBIVI / S&P BIVI unavailable / 15.97% |
LoseBIVI / S&P -9.23% / 42.23% |
| 2021-Q40/3 |
LoseBIVI / S&P -32.74% / 11.03% |
LoseBIVI / S&P BIVI unavailable / 15.00% |
LoseBIVI / S&P -8.59% / 96.40% |
| 2021-Q30/3 |
LoseBIVI / S&P -60.53% / 0.58% |
LoseBIVI / S&P BIVI unavailable / 10.77% |
LoseBIVI / S&P 4.73% / 69.42% |
| 2021-Q21/3 |
LoseBIVI / S&P -12.36% / 8.55% |
LoseBIVI / S&P BIVI unavailable / 6.58% |
WinBIVI / S&P 139.50% / 51.81% |
| 2021-Q12/3 |
WinBIVI / S&P 11.66% / 6.17% |
LoseBIVI / S&P BIVI unavailable / -1.06% |
WinBIVI / S&P 193.89% / 7.39% |
| 2020-Q42/3 |
WinBIVI / S&P 82.12% / 12.15% |
LoseBIVI / S&P BIVI unavailable / -3.72% |
WinBIVI / S&P 172.25% / -33.42% |
| 2020-Q31/3 |
LoseBIVI / S&P BIVI unavailable / 8.93% |
LoseBIVI / S&P BIVI unavailable / -2.04% |
WinBIVI / S&P 77.09% / -27.10% |
| 2020-Q20/3 |
LoseBIVI / S&P BIVI unavailable / 20.54% |
LoseBIVI / S&P BIVI unavailable / -0.46% |
LoseBIVI / S&P BIVI unavailable / -27.11% |
| 2020-Q10/3 |
LoseBIVI / S&P BIVI unavailable / -19.60% |
LoseBIVI / S&P BIVI unavailable / 3.47% |
LoseBIVI / S&P BIVI unavailable / -14.75% |
| 2019-Q40/3 |
LoseBIVI / S&P BIVI unavailable / 9.07% |
LoseBIVI / S&P BIVI unavailable / 5.36% |
LoseBIVI / S&P BIVI unavailable / 2.99% |
| 2019-Q30/3 |
LoseBIVI / S&P BIVI unavailable / 1.70% |
LoseBIVI / S&P BIVI unavailable / 5.02% |
LoseBIVI / S&P BIVI unavailable / 0.21% |
| 2019-Q20/3 |
LoseBIVI / S&P BIVI unavailable / 4.30% |
LoseBIVI / S&P BIVI unavailable / 6.64% |
LoseBIVI / S&P BIVI unavailable / 8.65% |
| 2019-Q10/3 |
LoseBIVI / S&P BIVI unavailable / 13.65% |
LoseBIVI / S&P BIVI unavailable / 8.12% |
LoseBIVI / S&P BIVI unavailable / 14.29% |
| 2018-Q40/3 |
LoseBIVI / S&P BIVI unavailable / -13.52% |
LoseBIVI / S&P BIVI unavailable / 9.05% |
LoseBIVI / S&P BIVI unavailable / 18.23% |
| 2018-Q30/3 |
LoseBIVI / S&P BIVI unavailable / 7.71% |
LoseBIVI / S&P BIVI unavailable / 10.21% |
LoseBIVI / S&P BIVI unavailable / 19.06% |
| 2018-Q20/3 |
LoseBIVI / S&P BIVI unavailable / 3.43% |
LoseBIVI / S&P BIVI unavailable / 9.03% |
LoseBIVI / S&P BIVI unavailable / 14.46% |
| 2018-Q10/3 |
LoseBIVI / S&P BIVI unavailable / -0.76% |
LoseBIVI / S&P BIVI unavailable / 7.68% |
LoseBIVI / S&P BIVI unavailable / 12.46% |
| 2017-Q40/3 |
LoseBIVI / S&P BIVI unavailable / 6.64% |
LoseBIVI / S&P BIVI unavailable / 7.03% |
LoseBIVI / S&P BIVI unavailable / 13.82% |
| 2017-Q30/3 |
LoseBIVI / S&P BIVI unavailable / 4.48% |
LoseBIVI / S&P BIVI unavailable / 5.68% |
LoseBIVI / S&P BIVI unavailable / 17.57% |
| 2017-Q20/3 |
LoseBIVI / S&P BIVI unavailable / 3.09% |
LoseBIVI / S&P BIVI unavailable / 4.83% |
LoseBIVI / S&P BIVI unavailable / 17.74% |
| 2017-Q10/3 |
LoseBIVI / S&P BIVI unavailable / 6.07% |
LoseBIVI / S&P BIVI unavailable / 3.67% |
LoseBIVI / S&P BIVI unavailable / 13.32% |
| 2016-Q40/3 |
LoseBIVI / S&P BIVI unavailable / 3.82% |
LoseBIVI / S&P BIVI unavailable / 2.09% |
LoseBIVI / S&P BIVI unavailable / 7.05% |
| 2016-Q30/3 |
LoseBIVI / S&P BIVI unavailable / 3.85% |
LoseBIVI / S&P BIVI unavailable / 0.20% |
LoseBIVI / S&P BIVI unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | BIVI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 44.08% | 20.78% |
| Annualized return | 44.08% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | BIVI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.73% | 83.14% |
| Annualized return | -69.27% | 12.86% |
10Y · 2020-09-18 to 2026-08-27
| Metric | BIVI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.78% | 319.30% |
| Annualized return | -45.79% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |